Nancy A. Kernan - Concepedia

Author

Nancy A. Kernan

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A. Scaradavou, Farid Boulad, N A Kernan, N Kernan, N. A. KERNAN, N. A. Kernan, N. KERNAN, N. Kernan, N.A. Kernan, NA Kernan

416

Publications

16.9K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University University of Minnesota Dana-Farber Cancer Institute Emmes (United States)

About

Nancy A. Kernan is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, transplantation, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	55	4.4K
2	Blood Transplantation	20	27	1.8K
3	Health Sciences	13	14	911
4	Cell Biology	8	8	808
5	Biomedical Engineering	3	3	97

Nancy A. Kernan

154

Publications

15.4K

Citations

H-Index

Page 1

	Year	Citations
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation Esperanza B. Papadopoulos, Marc Ladanyi, David Emanuel, New England Journal of Medicine	1994	1.1K
Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program Nancy A. Kernan, Glenn E. Bartsch, Robert C. Ash, New England Journal of Medicine	1993	848
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age Craig Kollman, Craig Howe, Claudio Anasetti, Blood	2001	699
Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Neutropenia in Patients with Congenital Agranulocytosis Mary Ann Bonilla, Mary Ruggeiro, Nancy A. Kernan, New England Journal of Medicine InflammationFunctional NeutrophilsBone Marrow FailureAutoimmune DiseaseCongenital Agranulocytosis	1989	497
Comparison of Immune Reconstitution After Unrelated and Related T-Cell–Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte Infusions TN Small, Esperanza B. Papadopoulos, Farid Boulad, Blood	1999	484
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation Ekaterina Doubrovina, Banu Oflaz-Sozmen, Susan E. Prockop, Blood	2011	416
Bone Marrow–Allograft Rejection by T Lymphocytes Recognizing a Single Amino Acid Difference in HLA-B44 Katharina Fleischhauer, Nancy A. Kernan, Richard J. O’Reilly, New England Journal of Medicine HistocompatibilityHlaMarrow GraftsImmunologyAntigen Processing	1990	340
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure Paul G. Richardson, Marcie Riches, Nancy A. Kernan, Blood	2016	317
Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies Joanne Kurtzberg, Vinod K. Prasad, Shelly L. Carter, Blood	2008	293
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL Kevin J. Curran, Steven Margossian, Nancy A. Kernan, Blood Cell TherapyMixed-phenotype Acute LeukemiaImmunologyImmunotherapeuticsT Cells	2019	272

Page 1